Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
Condition(s):Venous ThromboembolismLast Updated:September 9, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Venous ThromboembolismLast Updated:September 9, 2022Recruiting
Condition(s):Thrombosis; Myocardial InfarctionLast Updated:September 22, 2023Recruiting
Condition(s):Atrial FibrillationLast Updated:December 24, 2018Completed
Condition(s):Atrial FibrillationLast Updated:March 6, 2017Completed
Condition(s):Prevention of Atherothrombotic Events; Coronary Artery Disease (CAD); Symptomatic Peripheral Artery Disease (Symptomatic PAD)Last Updated:March 1, 2024Active, not recruiting
Condition(s):Clinical PharmacologyLast Updated:August 13, 2020Completed
Condition(s):Patients Receiving Rivaroxaban TreatmentLast Updated:February 14, 2017Completed
Condition(s):Clinical PharmacologyLast Updated:August 13, 2020Completed
Condition(s):Antiphospholipid Syndrome; Systemic Lupus Erythematosus; Stroke; Ischemic Stroke; Brain IschemiaLast Updated:December 11, 2023Active, not recruiting
Condition(s):HealthyLast Updated:January 24, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.